SCHEMBL1338675

SCHEMBL1338675

Cn1ccc(-c2ccc3[nH]c4c(cc(-c5ccc(Cl)cc5Cl)c(=O)n4C)c3c2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 10/20 0.37
▸ CNR2 P34972 10/20 0.37
▸ KCNH2 Q12809 1/20 0.36
▸ HSD11B1 P28845 2/20 0.36
▸ F2RL3 Q96RI0 1/20 0.35
▸ ADORA3 P0DMS8 3/20 0.35
▸ GABRA1 P14867 3/20 0.35
▸ EGFR P00533 1/20 0.35
▸ ALOX5 P09917 1/20 0.35
▸ ADRA2C P18825 1/20 0.35
▸ MAPK3 P27361 1/20 0.35
▸ OPRL1 P41146 1/20 0.35
▸ SLC6A3 Q01959 1/20 0.35
▸ SLC18A2 Q05940 1/20 0.35
▸ MAPK14 Q16539 1/20 0.35
▸ TMEM97 Q5BJF2 1/20 0.35
▸ SIGMAR1 Q99720 1/20 0.35
▸ CHEK1 O14757 2/20 0.34
▸ GABRP O00591 2/20 0.34
▸ GABRD O14764 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338440 0.83 MAP2 (0.45) CNR1CNR2HSD11B1F2RL3ADORA3
SCHEMBL1339374 0.82 CNR1 (0.38) CNR1CNR2HSD11B1F2RL3ADORA3
SCHEMBL1336854 0.82 PARP1 (0.42) CNR1CNR2HSD11B1F2RL3
SCHEMBL1338065 0.82 PARP1 (0.41) CNR1CNR2HSD11B1ADORA3GABRA1
SCHEMBL1337210 0.80 KDM4E (0.37) CNR1CNR2KCNH2HSD11B1F2RL3
SCHEMBL958804 0.80 F2RL3 (0.46) CNR1CNR2HSD11B1F2RL3
SCHEMBL1338048 0.80 NOTUM (0.38) CNR1CNR2HSD11B1F2RL3ADORA3
SCHEMBL1338628 0.80 HPSE (0.39) CNR1CNR2ADORA3GABRA1EGFR
SCHEMBL1339352 0.79 TLR8 (0.39) CNR1CNR2HSD11B1F2RL3ADORA3
SCHEMBL3567753 0.79 HTR1A (0.40) CNR1CNR2HSD11B1F2RL3MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 CNR1 262/4885CNR2 299/4885KCNH2 3010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback